Drug intelligence / Profile preview

HAT001

Development stage: Preclinical
Lead developer: HBM Alpha Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HAT001 is a novel anti-corticotropin-releasing hormone (CRH) neutralizing antibody developed by HBM Alpha Therapeutics, a biotechnology company incubated by Harbour BioMed. This therapeutic candidate is designed to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS) by specifically neutralizing CRH. The drug is currently in the IND-enabling stage, with plans to advance into clinical trials following a seed financing round.

Targets

CRH (Corticotropin-Releasing Factor)

Beyond the preview

Go deeper on HAT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAT001.

Explore the full profile